Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

54.39USD
25 May 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$54.39
Open
--
Day's High
--
Day's Low
--
Volume
1,060
Avg. Vol
11,566,859
52-wk High
$77.12
52-wk Low
$46.01

BMY

Chart for BMY

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $89,603.96
Shares Outstanding(Mil.): 1,647.43
Dividend: 0.39
Yield (%): 2.87

Financials

  BMY Industry Sector
P/E (TTM): 18.86 14.31 17.43
EPS (TTM): 2.88 -- --
ROI: 19.92 -7.26 -5.41
ROE: 33.58 -6.76 -4.69

BRIEF-Health Canada approves Bristol-Myers' opdivo(nivolumab)

* Health Canada approves opdivo (nivolumab) for the treatment of squamous cell carcinoma of the head and neck

May 17 2017

BRIEF-Jana Partners cuts sole share stake in Bristol-Myers Squibb

* Jana Partners cuts sole share stake in Bristol-Myers Squibb Co by 81.5 percent to 716,389 shares - SEC filing

May 15 2017

BRIEF-Appaloosa LP dissolves share stake in Bristol Myers, Qualcomm

* Appaloosa LP dissolves share stake in Bristol Myers Squibb Co - sec filing

May 12 2017

BRIEF-Bristol-Myers Squibb, Calithera Biosciences expand collaboration

* Bristol-Myers Squibb and Calithera Biosciences expand collaboration evaluating opdivo (nivolumab) in combination with CB-839 into non-small cell lung cancer and melanoma

May 10 2017

Bristol-Myers, Pfizer beat amended Eliquis case over bleeding risks

A federal judge has dismissed for a second time a lawsuit against Bristol-Myers Squibb and Pfizer Inc by a man who claimed he suffered severe internal bleeding after taking their blood thinner Eliquis.

May 09 2017

UPDATE 3-AstraZeneca immunotherapy wins first approval in bladder cancer

* AstraZeneca sets durvalumab price at $15,000/month (Adds analyst reaction, sales forecast, latest shares)

May 02 2017

BRIEF-China FDA approves country's first all-oral regimen for chronic Hepatitis C

* China FDA approves country's first all-oral regimen for chronic Hepatitis C, daklinza (daclatasvir) in combination with sunvepra (asunaprevir)

Apr 28 2017

Bristol-Myers' cancer drug Opdivo fuels Wall Street beat

NEW YORK Strong growth from Bristol-Myers Squibb Co's Opdivo and Yervoy cancer immunotherapies drove the company's first-quarter results past analysts' expectations and relieved some anxiety about increasing competition for the drugs.

Apr 27 2017

UPDATE 2-Bristol-Myers' cancer drug Opdivo fuels Wall Street beat

NEW YORK, April 27 Strong growth from Bristol-Myers Squibb Co's Opdivo and Yervoy cancer immunotherapies drove the company's first-quarter results past analysts' expectations and relieved some anxiety about increasing competition for the drugs.

Apr 27 2017

BRIEF-Bristol-Myers CFO: potential for 2017 U.S. growth for Opdivo

* Cfo says now believes "there is potential for Opdivo to grow in the U.S. this year," even with increased competition

Apr 27 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $127.53 --
Pfizer Inc. (PFE.N) $32.16 --
Merck & Co., Inc. (MRK.N) $65.04 --
Sanofi SA (SASY.PA) €87.59 +0.28
AstraZeneca plc (AZN.L) 5,235.00 +26.00
GlaxoSmithKline plc (GSK.L) 1,645.20 +27.20
Eli Lilly and Co (LLY.N) $78.34 --
Roche Holding Ltd. (ROG.S) CHF266.90 -0.30
Roche Holding Ltd. (RO.S) CHF267.75 +0.25

Earnings vs. Estimates